\begin{tabular}{lllllll}
\toprule
Domain & Durvalumab reports, n (\%) & ROR (95\% CI) & IC025 & PRR & EBGM05 & Signal status \\
\midrule
Pulmonary & 779 (8.3) & 119.09 (108.63, 130.55) & 5.24 & 109.25 & 63.02 & Positive \\
Dermatologic & 366 (3.9) & 73.52 (65.01, 83.15) & 4.60 & 70.68 & 46.06 & Positive \\
Gastrointestinal & 238 (2.5) & 56.50 (48.78, 65.44) & 4.19 & 55.08 & 37.86 & Positive \\
Hepatobiliary & 277 (3.0) & 42.86 (37.54, 48.93) & 4.08 & 41.62 & 30.95 & Positive \\
Endocrine & 392 (4.2) & 61.99 (55.18, 69.63) & 4.52 & 59.43 & 40.95 & Positive \\
Renal & 109 (1.2) & 26.02 (21.27, 31.83) & 3.18 & 25.73 & 20.53 & Positive \\
Neurologic & 102 (1.1) & 46.66 (37.50, 58.06) & 3.48 & 46.16 & 31.85 & Positive \\
Cardiac & 236 (2.5) & 70.15 (60.27, 81.63) & 4.32 & 68.40 & 43.95 & Positive \\
Hematologic & 243 (2.6) & 53.03 (45.90, 61.27) & 4.16 & 51.68 & 36.20 & Positive \\
Musculoskeletal & 186 (2.0) & 63.98 (54.06, 75.73) & 4.11 & 62.73 & 40.84 & Positive \\
Ocular & 15 (0.2) & 55.01 (31.09, 97.36) & 0.68 & 54.93 & 30.27 & Positive \\
Generalized immune-mediated & 38 (0.4) & 44.76 (31.40, 63.79) & 2.40 & 44.58 & 29.32 & Positive \\
\bottomrule
\end{tabular}
